Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2018
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Genentech
- 02 Mar 2018 Planned End Date changed from 11 Jan 2018 to 31 May 2019.
- 02 Mar 2018 Planned primary completion date changed from 11 Jan 2018 to 31 May 2019.
- 02 Mar 2018 Status changed from recruiting to active, no longer recruiting.